<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">QUETIAPINE FUMARATE</span><br/>(Ce-ti-a'peen)<br/><span class="topboxtradename">Seroquel<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antipsychotic, atypical</span><br/><b>Prototype: </b>Clozapine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 100 mg, 200 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Antagonizes multiple neurotransmitter receptors in the brain including serotonin (5-HT<sub>1A</sub> and 5-HT<sub>2</sub>) as well as dopamine D<sub>1</sub> and D<sub>2</sub> receptors. Mechanism of action is unknown, however, antipsychotic properties thought to be related to antagonized responses.
         Antagonizes histamine H<sub>1</sub> receptors resulting in possible somnolence, and adrenergic alpha<sub>1</sub> and alpha<sub>2</sub> receptors which may lead to orthostatic hypotension.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by a reduction in psychotic behavior.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of psychotic disorders, management of bipolar disorder.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Management of agitation and dementia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to quetiapine; pregnancy (category C), lactation; alcohol use. Safety and efficacy in children have not been
         established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver function impairment, older adults, cardiovascular disease (history of MI or ischemic heart disease, heart failure, arrhythmias,
         CVA, hypotension, dehydration, treatment with antihypertensives; history of seizures or suicide; breast cancer; Alzheimer's,
         Parkinson's disease; concurrent use of centrally acting drugs; patient at risk for aspiration pneumonia; debilitated patients;
         cerebrovascular disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Psychosis, Acute Mania</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initiate with 25 mg b.i.d., may increase by 2550 mg b.i.d. to t.i.d. on the second or third day as tolerated to a target
               dose of 300400 mg/d divided b.i.d. to t.i.d., may adjust dose by 2550 mg b.i.d. q.d. as needed (max: 800 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Initiate with 25 mg b.i.d., titrate more slowly than adult patients, target range 150200 mg/day in divided doses<br/><br/><span class="indicationtitle">Agitation, Dementia</span><br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Initiate with 25 mg b.i.d., may increase by 2550 mg b.i.d. q 27 d if needed (max: 200 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Titrate dose over 4 d usually to a target range of 300400 mg/d. Make further dose adjustments of 2550 mg 2 times/d
            at intervals of at least 2 d.
         </li>
<li>Retitrate to desired dose when patient has been off the drug for &gt;1 wk.</li>
<li>Follow recommended lower doses and slower titration for the older adults, the debilitated, and those with hepatic impairment
            or a predisposition to hypotension.
         </li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Asthenia, fever, hypertonia, dysarthria, flu syndrome, weight gain, peripheral edema. <span class="typehead">CNS:</span> <span class="speceff-common">Dizziness, headache, somnolence</span>. <span class="typehead">CV:</span> Postural hypotension, tachycardia, palpitations. <span class="typehead">GI:</span> Dry mouth, dyspepsia, abdominal pain, constipation, anorexia. <span class="typehead">Metabolic:</span> hyperglycemia, diabetes mellitus. <span class="typehead">Respiratory:</span> Rhinitis, pharyngitis, cough, dyspnea. <span class="typehead">Skin:</span> Rash, sweating. <span class="typehead"> Hematologic:</span>  Leukopenia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">barbiturates</span>, <b>carbamazepine,</b> <b>phenytoin,</b> <b>rifampin,</b> <b>thioridazine</b> may increase clearance of quetiapine. Quetiapine may potentiate the cognitive and motor effects of <b>alcohol,</b> enhance the effects of <span class="classification">antihypertensive agents</span>, antagonize the effects of <b>levodopa</b> and <span class="classification">dopamine agonists</span>. <b>Ketoconazole,</b> <b>itraconazole,</b> <b>fluconazole,</b> <b>erythromycin</b> may decrease clearance of quetiapine. <span class="typehead">Herbal:</span> <b>St. John's wort</b> may cause <b>serotonin</b> syndrome (headache, dizziness, sweating, agitation). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and completely absorbed from GI tract. <span class="typehead">Peak:</span> 1.5 h. <span class="typehead">Distribution:</span> 83% protein bound. <span class="typehead">Metabolism:</span> Extensively metabolized in the liver by CYP3A4. <span class="typehead">Elimination:</span> 73% excreted in urine, 20% in feces. <span class="typehead">Half-Life:</span> 6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Reassess need for continued treatment periodically.</li>
<li>Withhold the drug and immediately report S&amp;S of tardive dyskinesia or neuroleptic malignant syndrome (see Appendix F).</li>
<li>Lab tests: Periodically monitor liver function, lipid profile, thyroid function, blood glucose, CBC with differential.</li>
<li>Monitor ECG periodically, especially in those with known cardiovascular disease.</li>
<li>Perform baseline cataract exam when therapy is started and at 6 mo intervals thereafter.</li>
<li>Monitor patients with a history of seizures for lowering of the seizure threshold.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Carefully monitor blood glucose levels if diabetic.</li>
<li>Exercise caution with potentially dangerous activities requiring alertness, especially during the first week of drug therapy
            or during dose increments.
         </li>
<li>Make position changes slowly, especially when changing from lying or sitting to standing to avoid dizziness, palpitations,
            and fainting.
         </li>
<li>Avoid alcohol consumption and activities that may cause overheating and dehydration.</li>
<li>Inform physician immediately if you become pregnant.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>